Facts and figures




16 production sites on 5 continents.

Affiliates or offices in 77 countries.

Products marketed in more than 165 countries.


Approximately 41,700 employees (FTEs September 2017).

19% within research and development
32% in production and production administration
37% in international sales and marketing
12% in administration

Regional distribution (FTEs)

Approximately 41% of employees are located in Denmark (17,105 FTEs) and 59% in the rest of the world:

Africa, Asia, Middle East & Oceania: 6,627

China (4,206) & Taiwan: 4,299

Denmark: 17,105

Europe (excl. HQ): 4,312

Japan (1,124) & Korea: 1,248

Latin America: 1,805

North America (US 5,961 & Canada 299): 6,260

(includes all Novo Nordisk and NNE employees in the respective locations)

Product areas

We have five product areas:
Diabetes care
Obesity and weight management
Haemophilia management
Growth hormone therapy
Hormone replacement therapy

According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.

For patient and disease information, including pens and needles, please look under Patients.

Quarterly sale
Q3 2017

26,614 million Danish kroner

Annual sale

111,780 million Danish kroner 
(Full year results 2016. See Financial Statement for more information)

Sales by business segment
Q3 2017

Diabetes and obesity care total:
21,563 million Danish kroner

Biopharmaceuticals total:
4,411 million Danish kroner

Sales by region
Q3 2017

North America Operations:
13,532 million Danish kroner

USA: 12,967 million Danish kroner

International Operations: 
13,082 million Danish kroner

Region Europe: 5,190 million Danish kroner
Region AAMEO: 2,929 million Danish kroner
Region China: 2,531 million Danish kroner
Region Japan & Korea: 1,462 million Danish kroner
Region Latin America: 970 million Danish kroner


Novo Nordisk A/S

Bagsværd, Denmark, 
CVR nr. 24 25 67 90



Financial highlights

Download annual reports, interim reports,
investor presentations and more.

Download centre

Share information

Learn more about Novo Nordisk shares.

Shareholder rights

Novo Nordisk products

Facts about Novo Nordisk products

Product facts